8/15/2006
9:28 Business Wire

Dr. Paul Coussens Joins HepaLife’s Scientific Advisory Board.
Wild birds now nesting in Alaska and Canada will begin their migration south this fall; monitoring of migratory birds to prevent a deadly bird flu virus now is in effect for the entire nation.

7/24/2006
13:08 Business Wire

HepaLife Targets Avian Flu: New Report Alerts Senior State Officials and Governors to Pandemic Influenza.
National Governors Association (NGA) report warns: “The effects of a pandemic flu will be broad, deep, and simultaneous…”; Medical response capabilities will be limited, and potentially depleted if effective vaccines are not developed in sufficient quantities.

7/10/2006
9:15 Business Wire

HepaLife Enters Into Exclusive License Agreement for Development of New Flu Vaccines.
Worldwide license agreement supported by 5 issued patents for the development of new flu vaccines to protect against the spread of influenza viruses among humans, including potentially the high pathogenicity H5N1 virus.

6/13/2006
9:15 Business Wire

HepaLife’s Liver Cells Detect Acetaminophen Poisoning, A Leading Cause of Liver Failure.
Successfully detecting dangerous compounds in new and existing drugs is critical to the development of new toxicology testing platforms.

5/30/2006
9:15 Business Wire

HepaLife Achieves Major Cell Biology Objective in Artificial Liver Device Research
HepaLife’s liver cells demonstrate ability to function and survive without feeder cell support, following successful room temperature and human plasma survival outcomes; findings crucial to artificial liver device.

5/22/2006
9:15 Business Wire

HepaLife’s Liver Cell Function Plays Vital Role in Toxic, Brain Damaging Disease - a New Priority for NIH.
PICM-19 cells help safely excrete highly toxic by-product – ammonia - which causes brain damage, coma, and death; NIH launches multimillion dollar research initiative.

4/26/2006
9:15 Business Wire

HepaLife’s Artificial Liver Research Passes Critical Human Plasma Milestone.
HepaLife’s liver stem cells achieve 95%-plus survival rate in critical human plasma tests; favorable findings follow positive results for important room temperature survival and function.

3/9/2006
9:15 Business Wire

HepaLife To Accelerate Research Activities And Bolster Management and Research Teams.
Encouraging Research Outcomes, Evolving Corporate Events, and Continued Rise in Acetaminophen-Related Acute Liver Failure, Spur HepaLife’s Accelerated Expansion Plans.

10/5/2005
9:15 Business Wire

Positive Results from Latest Experiments Released by HepaLife’s Collaborating USDA Research Team.
USDA Bioengineer, Dr. Ayesha Mahmood, Presents Brand New ‘Survival and Function’ Data in Support of HepaLife’s PICM-19H Liver Cells at National Biomedical Engineering Society Meeting.

9/19/2005
9:15 Business Wire

Important Room Temperature Storage Results To Be Released By HepaLife’s Collaborating USDA Research Team.
Ability to store liver cells in artificial liver device at room temperature for extended periods would allow for ease of transport and reduce storages costs; Liver cells considered to be the most critical component of an artificial liver device.

8/12/2005
9:15 Business Wire

HepaLife Announces Appointment Of New President and Chief Executive Officer.
Vancouver, BC – August 12, 2005 – HepaLife Technologies, Inc. (OTCBB: HPLF), a development stage biotechnology company focused on the identification, development and eventual commercialization of technologies and products for liver toxicity detection and the treatment of various forms of liver dysfunction and disease, is pleased to announce the appointment of Mr. Harmel S. Rayat, a current director, to the position of president and chief executive officer.

7/11/2005
9:15 Business Wire

HepaLife to Obtain Up to $15,000,000 in Equity Financing.
Vancouver, BC – July 11, 2005 – HepaLife Technologies, Inc. (OTCBB: HPLF), a development stage biotechnology company focused on the identification, development and eventual commercialization of technologies and products for liver toxicity detection and th

5/24/2005
9:15 Business Wire

Emergency Medicine Specialist at Front Lines of Adverse Drug Reactions & Acute Liver Failure Joins HepaLife to Assist Ongoing Development of Artificial Liver Device & Hepatotoxicity Testing Platform.
Vancouver, BC – May 24, 2005 – HepaLife Technologies, Inc. (OTCBB: HPLF), a development stage biotechnology company focused on the identification, development and eventual commercialization of technologies and products for liver toxicity detection and the

4/11/2005
9:15 Business Wire

HepaLife Surpasses Research Objectives: Continues to Advance Optimization of Proprietary Liver Cell Line for Final Use in Artificial Liver Device.
New experiments to study factors that may extend the time liver cells remain functional at room temperature, potentially improving long distance transport and allowing for faster utilization in clinical or hospital setting.

3/23/2005
9:15 Business Wire

Drug Complaints Reach Record High at US Food & Drug Administration
HepaLife Reiterates Expected Rise in Drug-Induced Liver Injury 'USA Today' reveals over 422,500 adverse-events filed with the FDA -- an increase of nearly 14% from previous year. Earlier CDC report finds almost half of all Americans now using prescription

2/22/2005
9:15 Business Wire

HepaLife Announces Addition of Toxicology Scientist, to Develop Testing Platform for Liver Toxicity - the Leading Cause of Drug Withdrawals from Clinical Use.
NIH report: identifies need for in vitro testing systems in response to drug-induced liver damage; cites artificial liver device as “most helpful” for acute liver failure patients.

2/2/2005
12:35 Business Wire

HepaLife to Expand Research Team
VANCOUVER, British Columbia--(BUSINESS WIRE)--Feb. 2, 2005--HepaLife Technologies, Inc. (OTCBB:HPLF - News), a development stage biotechnology company focused on the research, development and eventual commercialization of technologies and products for liv

1/18/2005
9:15 Business Wire

HepaLife Comments on Federal Legislation Created to Facilitate the Commercialization of Technologies Developed by Federal Laboratories.
Vancouver, BC – January 18, 2005 – HepaLife Technologies, Inc. (OTCBB: HPLF), a development stage biotechnology company focused on the research, development and eventual commercialization of technologies and products for liver toxicity detection and the t

1/4/2005
10:42 Business Wire

NIH Issues Research Action Plan for Funding
Vancouver , BC – January 4, 2005 – HepaLife Technologies, Inc. (OTCBB: HPLF), a development stage biotechnology company focused on the research, development and eventual commercialization of technologies and products for liver toxicity detection and the t

12/15/2004
9:15 Business Wire

Drug induced liver injury expected to increase with almost half of all Americans now using prescription drugs.
Vancouver, BC – December 15, 2004 - HepaLife Technologies, Inc. (OTCBB: HPLF), a development stage biotechnology company focused on the research, development and eventual commercialization of technologies and products for liver toxicity detection and the

12/8/2004
9:20 Business Wire

Renowned Organ Transplant Surgeon and Widely- Published Liver Expert to Assist Ongoing Development of HepaLife’s Proprietary Artificial Liver Device
Vancouver , BC – December 8, 2004 - HepaLife Technologies, Inc. (OTCBB: HPLF) a development stage biotechnology company focused on the research, development and eventual commercialization of technologies and products for liver toxicity detection and the t

9/22/2004
9:30 Business Wire

Proprietary Liver Cell Line Performs Beyond Expectations
Results from improved cell line continue to surpass initial expectations; Key enzyme systems indicate highly favorable results; PICM-19P cells now indexed as 'PICM-19H'

8/9/2004
9:30 Business Wire

Professor Dr. med. Michael Ott Joins HepaLife Scientific Advisory Board
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 9, 2004--HepaLife Technologies, Inc. (OTCBB:HPLF - News): Associate Professor of Experimental Hepatology at Leading Liver Transplant University-Hospital to Guide Ongoing Research, Development, and Commerc

8/2/2004
9:30 PrimeZone Media Network

Dr. Ayesha Mahmood Joins Research Team
VANCOUVER, British Columbia, Aug. 2, 2004 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF), a development stage biotechnology company focused on the research, development and eventual commercialization of technologies and products for liver toxicit

7/6/2004
9:30 PrimeZone Media Network

HepaLife Receives Approval for Trading on Frankfurt Stock Exchange
VANCOUVER, British Columbia, July 6, 2004 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF), an early stage biotechnology company focused on developing the first of its kind artificial liver device and proprietary in vitro toxicology and pre-clinica

6/15/2004
10:09 PrimeZone Media Network

HepaLife Announces Formation of Distinguished Scientific Advisory Board
Cell Research Expert and Medical Technology Business Innovator to Guide Ongoing Research, Development, and Commercialization of HepaLife's Proprietary, Cell-Driven Technologies

6/1/2004
6:30 PrimeZone Media Network

HepaLife Announces Expansion and Extension of Cooperative Research Agreement
VANCOUVER, British Columbia, June 1, 2004 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF), a development stage biotechnology company focused on the research, development and eventual commercialization of technologies and products to treat various

5/14/2004
14:28 PrimeZone Media Network

HepaLife Expands into Developing Technology for Hepatotoxicity, the Most Common Reason Cited for the Withdrawal of an Approved Drug, Pre-Clinical Drug Failures, and for Refusal of Drug Approval by the FDA
VANCOUVER, B.C., May 14, 2004 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF), a development stage biotechnology company focused on technologies and products to treat various forms of liver dysfunction and disease, is pleased to announce its plans

4/14/2004
14:37 PrimeZone Media Network

HepaLife Approved for Listing on Berlin Bremen Exchange
VANCOUVER, B.C., April 14, 2004 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF) is pleased to announce that effective immediately the Company has been approved for dual listing on the Berlin Bremen Stock Exchange under the symbol HL1 (CUSIP number

1/7/2004
10:00 PrimeZone Media Network

HepaLife Announces Results of First Phase Research
VANCOUVER, British Columbia, Jan. 7, 2004 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF) is pleased to announce the initial results of its first phase of research towards the development of a bio-artificial liver device for use by human patients

12/17/2003
9:20 PrimeZone Media Network

HepaLife to Release Latest Research Results
VANCOUVER, British Columbia, Dec. 17, 2003 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB: HPLF) is pleased to announce that it will be releasing the results of recent scientific research on the patented PICM-19 cell line for potential application in a

11/20/2003
14:35 PrimeZone Media Network

HepaLife appoints Mr. Jasvir S. Kheleh as Director
VANCOUVER, British Columbia, Nov. 20, 2003 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF) is pleased to announce the appointment of Mr. Jasvir S. Kheleh as a Director, a position previously held by Mr. Jeet S. Sidhu since January 15, 2001.

10/7/2003
9:30 PrimeZone Media Network

Hepatitis Now More Prevalent Than AIDS; HepaLife Developing Artificial Liver in Response to Growing Base of Liver Disease Sufferers
VANCOUVER, British Columbia, Oct. 7, 2003 (PRIMEZONE) -- Accounting for an estimated 40% of all deaths due to chronic liver disease, hepatitis C is a deadly virus that enters the blood system and attacks the liver. Unfortunately, because there is no cure

9/23/2003
11:17 PrimeZone Media Network

Mr. Arian Soheili Appointed as Director and New President & CEO of HepaLife
VANCOUVER, British Columbia, Sept. 23, 2003 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF) is pleased to announce the appointment of Mr. Arian Soheili as a Director of the Company and its new President and CEO, a position previously held by Mr. H

9/3/2003
6:30 PrimeZone Media Network

Dr. Mark A. Saarinen Joins Research Team
VANCOUVER, B.C., Sept. 3, 2003 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF), today announced the recent addition of Dr. Mark A. Saarinen, a bioengineer, who will lead ongoing research and development work on the patented application of the pate

8/4/2003
10:00 PrimeZone Media Network

Alcohol Abuse Major Cause of Liver Disease
VANCOUVER, British Columbia , Aug. 4, 2003 (PRIMEZONE) -- Each year, hundreds of thousands of individuals worldwide experience acute or chronic liver failure caused by viral hepatitis, degenerative diseases, trauma, drug overdoses and alcohol abuse. The l

7/29/2003
11:54 PrimeZone Media Network

Scope of HepaLife's Artificial Liver Research
VANCOUVER, British Columbia, July 29, 2003 (PRIMEZONE) -- Under a Cooperative Research and Development Agreement (CRADA) with the USDA's Agricultural Research Service (ARS), the primary tool linking government and industry researchers, HepaLife Technologi

7/24/2003
10:22 PrimeZone Media Network

Thornhill Advisors Engaged as Media Relations Counsel
VANCOUVER, B.C., July 24, 2003 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTCBB:HPLF) today announced it has engaged Thornhill Advisors, a full service, pro-active financial relations and corporate communications company, to serve as its investor and fin

7/21/2003
9:30 PrimeZone Media Network

25 Million Americans Afflicted With Liver Disease
VANCOUVER, British Columbia, July 21, 2003 (PRIMEZONE) -- Presently, through a Cooperative Research and Development Agreement (CRADA) with the USDA's Agricultural Research Service, the primary tool linking government and industry researchers, HepaLife Tec

7/2/2003
9:30 PrimeZone Media Network

HepaLife Initiates I.R. Program
VANCOUVER, British Columbia, July 2, 2003 (PRIMEZONE) -- HepaLife Technologies, Inc. (OTC BB:HPLF.OB - News) today announced that it has initiated an ongoing investor relations program in order to enhance the Company's visibility in the investment communi